Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke "EARLY"


Phase 2 Results

Summary of Purpose

This pilot trial will be the first step toward direct comparison of delivery of endovascular reperfusion therapy to intravenous recombinant tissue plasminogen activator (rt-PA) in a time-to-treatment framework shown as most effective by the NINDS rt-PA Stroke Trial. A randomized trial is justified for the following... Trial Stopped: Poor recruitment

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 12 August 2016.

1 Jan 2013 1 Jun 2013 1 Sep 2015 1 Sep 2015 1 Aug 2016 12 Aug 2016
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind (Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


Not available